Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients
| Autor: | Ciro Pio Rosario Coccia, Anna Ferrari, Diego Pinetti, Emilio Sternieri, Alfio Bertolini |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Migraine without Aura Agonist Metabolic Clearance Rate medicine.drug_class Injections Subcutaneous Administration Oral Triptans Absorption Subcutaneous injection Pharmacokinetics Oral administration medicine Humans Pharmacology (medical) Dosing Variability Sumatriptan Response Chromatography High Pressure Liquid Pharmacology business.industry General Medicine Middle Aged musculoskeletal system medicine.disease Serotonin Receptor Agonists Migraine Area Under Curve Anesthesia cardiovascular system Female business Half-Life medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 64:489-495 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/s00228-007-0443-9 |
| Popis: | The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan. To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics. We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector. Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The systemic exposure to sumatriptan during the first 2 h, which are the most important for rapid onset of action and for antimigraine efficacy, was significantly greater in group A than in group B (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink